Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase

Endocrine therapy resistance is a primary cause of clinical breast cancer treatment failure. The p38 mitogen activated protein kinase (MAPK) signaling pathway is known to promote ligand independent tumor growth and resistance to endocrine therapy. In this study, we investigated the therapeutic poten...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Antoon, James W, Bratton, Melyssa R, Guillot, Lori M, Wadsworth, Scott, Salvo, Virgilio A, Elliott, Steven, McLachlan, John A, Burow, Matthew E
Format: Artigo
Langue:Inglês
Publié: e-Century Publishing Corporation 2012
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3410584/
https://ncbi.nlm.nih.gov/pubmed/22860234
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires